Earlier this month, we shared news of a Phase III trial of inosine, a potential disease-modifying treatment for Parkinson's disease (PD), based on findings from research funded by The Michael J. Fox Foundation.
This has been followed by two new developments with promise to improve the lives of those living with PD:
- Researchers used data from the MJFF-sponsored Parkinson's Progression Markers Initiative to set five criteria for differentiating people with PD that can possibly predict who will get Parkinson's disease.
- Acadia Pharmaceuticals announced that it is seeking FDA approval of its drug Nuplazid for the treatment of psychosis associated with PD.
Help us drive the momentum we see in the field even further. Donate today to support Parkinson's research that will help speed a cure.